NDA 050758 · Roche Palo
Cellcept
Mycophenolate Mofetil Hydrochloride · Injection
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Aug 12, 1998
Approved uses
4
Original approval plus efficacy supplements
Registered trials
1,151
212 Phase 3, 106 recruiting
FAERS reports
138,802
126,629 serious, 24,926 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1) , Use in Special Populations (8.1 , 8.3) ] . Increased risk of development of lymphoma and other malignancies, particularly of the skin [see Warnings and Precautions (5.2) ] . Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes [see Warnings and Precautions (5.3) ] . WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS See full prescribing information for...
What it is approved for
From the label in effect Aug 5, 2026.
CELLCEPT [mycophenolate mofetil (MMF)] is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ], heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ] , in combination with other immunosuppressants. CELLCEPT is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. ( 1 )
Mechanism: Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 6, 2022 Supplement 49 · Efficacy LetterLabel
- Jun 6, 2022 Supplement 47 · Efficacy LetterLabel
- Jul 28, 2000 Supplement 4 · Efficacy LabelReviewLetter
- Aug 12, 1998 Original approval · Type 3 - New Dosage Form OtherReviewOther Important Information from FDA
1 products under this application
- CELLCEPT · MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Mycophenolate Mofetil" as an intervention, any sponsor and status, largest first.
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesPivotal-lookingActive, not recruiting
University of Sao Paulo General HospitalAcademic, hospital or other
NCT05879419 · 2,005 participants (planned) · Start May 23, 2023 · Primary completion Dec 1, 2025
Drug: Recombinant Herpes Zoster Vaccine (RZV) · For: Rheumatoid Arthritis; Spondylitis, Ankylosing; Spondyloarthritis and 8 more
Sites: São Paulo, Brazil
- A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney RejectionPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00717470 · 1,252 participants · Start May 14, 2008 · Primary completion Mar 2, 2010
Drug: Prograf®; Advagraf® and 3 more · For: Kidney Transplantation
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Innsbruck, Austria · 110 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without SteroidsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01304836 · 1,166 participants · Start Jan 22, 2011 · Primary completion May 22, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: Perth, Australia; Sydney, Australia; Brussels, Belgium · 100 sites in all
- Fixed Dose MMF vs Concentration Controlled MMF After Renal TransplantationPivotal-lookingCompleted
Erasmus Medical CenterAcademic, hospital or other
NCT00166244 · 901 participants · Start May 2003 · Primary completion Mar 2005
Drug: Mycophenolate Mofetil · For: De Novo Renal Transplant Recipient.
Sites: New Lambton, Australia; Brisbane, Australia; Clayton, Australia · 67 sites in all
- Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver TransplantationPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01011205 · 893 participants · Start Sep 30, 2009 · Primary completion Jan 4, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Liver Transplantation
Sites: Buenos Aires, Argentina; Innsbruck, Austria; Minsk, Belarus · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use20,344
- drug ineffective11,621
- product use in unapproved indication7,426
- diarrhoea7,211
- pyrexia5,839
- pneumonia5,519
- cytomegalovirus infection5,007
- fatigue4,809
- nausea4,737
- condition aggravated4,653
- dyspnoea4,390
- vomiting4,236
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 773 |
| 2005 | 865 |
| 2006 | 1,201 |
| 2007 | 1,359 |
| 2008 | 1,722 |
| 2009 | 2,396 |
| 2010 | 2,298 |
| 2011 | 2,496 |
| 2012 | 2,714 |
| 2013 | 2,861 |
| 2014 | 3,111 |
| 2015 | 3,703 |
| 2016 | 4,508 |
| 2017 | 7,331 |
| 2018 | 8,478 |
| 2019 | 10,703 |
| 2020 | 11,592 |
| 2021 | 10,644 |
| 2022 | 10,127 |
| 2023 | 11,130 |
| 2024 | 14,284 |
| 2025 | 14,302 |
| 2026 | 10,195 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cellcept (Mycophenolate Mofetil)
2024 spending
$4.1M
Beneficiaries
361
1,688 claims
Per beneficiary
$11,320
$14.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,373,785 |
| 2021 | $6,817,241 |
| 2022 | $5,963,581 |
| 2023 | $5,317,386 |
| 2024 | $4,086,555 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Appel GB, Contreras G, Dooley MA, et al. · J Am Soc Nephrol 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis.
Lombardi F, Stewart I, Fabbri L, et al. · BMJ Open Respir Res 2024 · Meta-Analysis, Systematic Review
- Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis.
Mostafa N, Phan K, Smith S · J Dermatolog Treat 2022 · Meta-Analysis, Systematic Review
- Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis.
Phan K, Smith SD · J Dermatolog Treat 2020 · Meta-Analysis, Systematic Review
- Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, et al. · J Am Soc Nephrol 2022 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
Jiang N, Jin S, Yu C, et al. · Front Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.